CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 50 target
Drug / intervention
Remimazolam besylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05975255
NCT05975255Phase 2Unknown
CompareCT.gov

Effective Dose of Remimazolam for Loss of Consciousness in Children: A Prospective Dose Finding Study

Seoul National University Hospital·interventional·Posted Aug 3, 2023·Updated Nov 22, 2023

In Brief

A Phase 2 clinical trial evaluating Remimazolam besylate for Drug Effect. Targeting 50 participants across 1 site.

Detailed Summary

This study aims to find effective dose of remimazolam for inducing loss of consciousness in children aged 2 to 8 years old. We will explore ED90 of remimazolam for loss of consciousness in 2 minutes after intravenous injection, via a up-and-down method with biased-coin design.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Effect
CountriesSouth Korea
Collaborators--

Timeline

Phase 2UnknownOverdue
202420252026
First PostedAug 3, 2023
Enrollment StartNov 16, 2023
Primary CompletionOct 31, 2024
Study CompletionDec 31, 2024
TodayJul 1, 2026
Enrollment to primary: 12 monthsPosted 2.9 years ago

Interventions

Remimazolam besylatedrug

Intravenous administration of predetermined dose of Byfavo for 30 seconds